Amedisys (NASDAQ:AMED) was downgraded by equities research analysts at Craig Hallum from a “buy” rating to a “hold” rating in a research report issued on Friday, The Fly reports. They presently have a $104.00 target price on the health services provider’s stock, down from their previous target price of $116.00. Craig Hallum’s price target would suggest a potential upside of 5.07% from the company’s current price.
A number of other equities research analysts have also recently weighed in on AMED. Bank of America raised Amedisys from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $88.00 to $97.00 in a research note on Tuesday, July 3rd. ValuEngine raised Amedisys from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 30th. Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 3rd. Canaccord Genuity began coverage on Amedisys in a research note on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Amedisys has a consensus rating of “Buy” and an average target price of $97.08.
Shares of NASDAQ AMED traded down $10.10 during trading on Friday, reaching $98.98. The stock had a trading volume of 451,913 shares, compared to its average volume of 318,037. Amedisys has a fifty-two week low of $45.60 and a fifty-two week high of $127.38. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $3.46 billion, a PE ratio of 44.79, a PEG ratio of 1.64 and a beta of 1.00.
In related news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $121.71, for a total transaction of $48,440.58. Following the completion of the transaction, the insider now directly owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.60% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new stake in Amedisys during the 2nd quarter worth about $149,000. Creative Planning purchased a new stake in Amedisys during the 3rd quarter worth about $257,000. Moneta Group Investment Advisors LLC purchased a new stake in Amedisys during the 2nd quarter worth about $181,000. Cubist Systematic Strategies LLC lifted its holdings in Amedisys by 1,086.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock worth $203,000 after buying an additional 2,172 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC purchased a new stake in Amedisys during the 1st quarter worth about $151,000. 93.17% of the stock is owned by hedge funds and other institutional investors.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Read More: Insider Trading – What You Need to Know
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.